首页%0 Journal Article %A Vincente Villanueva %A Beatriz Giráldez %A Manuel Toledo %A Gerrit-Jan de Haan %A Eduardo Cumbo %A Antonio Gambardella %A Marc De Backer %A Lars Joeres %A Marcus Brunnert %A Peter Dedeken %A Jose Serratosa %T Effectiveness of lacosamide monotherapy in clinical practice: a retrospective chart review in patients with focal seizures (P5.230) %D 2017 %J Neurology %P P5.230 %V 88 %N 16 Supplement %X Objective: To assess effectiveness and tolerability of lacosamide monotherapy in patients with focal seizures (FS).Background: Lacosamide is approved as monotherapy for FS in the USA!缺日临床实践发布数据.设计/方法:回溯评估欧洲16岁观察点12/3月结果包括业务方案3保留率(12+3个月)、业务方案2收缴自由率(6+3个月)和业务方案3和治疗突发不良药反应(TEADRs)。++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++一线保留率和转换为单治子类为60.2%(59/98!95%置信区间50.5%-69.9%,62.5%3-67.6%)卡普兰-梅耶估计12个月的保留率分别为81.2%和91.4%第一线和转入单疗法++65岁病人保留率分别为6.0%(40.8-79.2%)和68.9%(6.0-77.9%)第一行转换为单治实验2中66.3%第一行和63.0%转为单治病人免费(odds-ratio 1.15[95%CI 0.713-1.839])。OP3中60.2%第一线和52.5%转换为单治病人免费(odds-ratio 1.80[95%CI1.080-3.001])。65岁病人2单行和转单治分别占72.0%和68.0%,3例68.0%和56.3%。整体而言,2/439(11.8%)病人报告TEADRs(16.4%为#65岁病人),最常见的(%1%)头晕(5.0%)、头痛(2.1%)和求同存异(1.6%)。Villanueva因Eisai、UCB、Bial、Novartis和Esteve参加咨询局或行业赞助的研讨会而获得个人补偿Giraldez博士因与UCBPharma通话活动而获得个人补偿博士托莱多因UCB Pharma、BIAL、EISAI、Esteve和Shire咨询公司的活动而获得个人补偿博士托莱多得到了EISAI和BIAL的研究支持博士de Haan个人因UCBPharma担任演讲人和/或咨询人而获得补偿博士Cumbo没什么可透露博士Gambardella因咨询、科学咨询委服务或科学会议讲演EISA博士和UCBDe Backer因UCBPharma雇员活动而获得个人补偿博士Joeres因UCBPharma活动获得个人补偿博士Brunnert因UCB生物科学GmbH雇员活动而获得个人补偿博士Deken因UCBPharma雇员活动而获得个人补偿塞拉托萨博士因与UCB、Esteve、EisaiLtd、Bial和Cebronics%U